In this clinical conversation, two Sydney-based doctors discuss the role of the new GIP/GLP-1RA class (tirzepatide) along with the more established treatment options such as insulin and the SGLT2i and GLP-1RA classes.

Watch endocrinologist Professor Ted Wu as he explains the expected responses to tirzepatide and how these compare with other antiglycaemic medications, particularly the GLP-1RA class, for HbA1c lowering and weight reduction.

Disclosure: Dr Peter Piazza has sat on Advisory Boards, chaired/spoken at educational meetings, and received travel and accommodation costs from a number of pharmaceutical companies, including Eli Lilly. Dr Ted Wu has received research funds, participated on educational/advisory panels, received travel support and contracted speakers for: Eli Lilly, AstraZeneca, BMS, MSD, Novo Nordisk, Sanofi-Aventis, Janssen Cilag, Roche, Abbott, GSK, Novartis, Takeda and Boehringer Ingelheim. 

January 31, 2024: Update on stock availability of tirzepatide (Mounjaro). The TGA has been notified by Eli Lilly Australia that the 5mg dose vial is now available at wholesalers in Australia in limited quantities. The other doses remain temporarily out of stock due to larger than expected demand.